What do systematic reviews say?

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: tezacaftor plus ivacaftor vs placebo or ivacaftor alone

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 946 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1139 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 204 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1061 participants
  Moderate

Long‐term red cell transfusion vs no transfusion

• Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 196 participants
  Low

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Arginine butyrate plus standard care alone vs usual care

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Propionyl‐L‐carnitine vs placebo

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

RGD peptide matrix vs placebo

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Solcoseryl vs antiseptic agent

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Duoderm® (hydroactive dressing) vs antiseptic agent

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Isoxsuprine vs placebo

The review found no eligible studies for this question.

• Interventions for treating leg ulcers in people with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Long‐term red cell transfusion vs no transfusion

The review found no eligible studies for this question.

• Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

The review found no eligible studies for this question.

• Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

The review found no eligible studies for this question.

• Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found